Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Acid Suppression Therapy with Vonoprazan vs. Regular PPIs

First-Line Therapy Recommendations

  • The American Gastroenterological Association recommends using regular PPIs as first-line therapy for non-erosive reflux disease (NERD) as vonoprazan has not demonstrated clear clinical superiority for this condition 1, 2
  • The American Gastroenterological Association recommends using regular PPIs as first-line therapy for mild erosive esophagitis (LA Grade A/B) as vonoprazan shows similar healing efficacy but at significantly higher cost 1, 2
  • The American Gastroenterological Association recommends using standard PPIs as first-line therapy for peptic ulcer disease (PUD) as vonoprazan has only demonstrated non-inferiority (not superiority) for gastric ulcer healing (94% vs 94%) and duodenal ulcers (96% vs 98%) 3
  • The American Gastroenterological Association recommends using regular PPIs as first-line therapy for ulcer prophylaxis in patients on low-dose aspirin or NSAIDs as vonoprazan is only non-inferior to lansoprazole for ulcer recurrence prevention 3
  • The American Gastroenterological Association recommends using vonoprazan as first-line therapy for H. pylori eradication due to significantly higher eradication rates (92% vs 80%) 1, 3
  • The American Gastroenterological Association recommends considering vonoprazan as first-line therapy for severe erosive esophagitis (LA Grade C/D) due to superior maintenance of healing compared to lansoprazole (recurrence rates 5-13% vs 39%) 3, 2

Second-Line Therapy Recommendations

  • The American Gastroenterological Association recommends considering vonoprazan for patients with PPI-resistant GERD who fail twice-daily PPI therapy 1, 2
  • The American Gastroenterological Association recommends considering vonoprazan for severe erosive esophagitis maintenance if recurrence occurs on PPI therapy 3, 2

Clinical Considerations

  • The American Gastroenterological Association notes that vonoprazan is significantly more expensive than both standard and double-dose PPIs in the United States 1, 2
  • The American Gastroenterological Association notes that even modest clinical superiority may not make vonoprazan cost-effective as first-line therapy 1

Common Pitfalls to Avoid

  • The American Gastroenterological Association recommends avoiding the use of vonoprazan for mild GERD or PUD when PPIs would be more cost-effective 1, 2
  • The American Gastroenterological Association recommends considering the significantly higher cost of vonoprazan compared to PPIs when making treatment decisions 1
  • The American College of Gastroenterology recommends ensuring proper PPI dosing (30-60 minutes before meals) and considering twice-daily dosing before switching to vonoprazan for GERD 4
  • The American College of Gastroenterology recommends emphasizing lifestyle modifications such as weight management, avoiding late meals, and elevating the head of the bed regardless of medication choice 5